Verve Therapeutics reports Q2 EPS (59c), consensus (68c)

Reports Q2 revenue $6.692M, consensus $2.4M. “The second quarter has been a period of continued execution for Verve, underscored by our commitment to protecting patients from cardiovascular disease through single-course gene editing medicines,” said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics. “Our Heart-2 Phase 1b clinical trial of VERVE-102 continues to progress as we focus on enrolling patients and expanding the trial’s geographic footprint, highlighted by our recent regulatory clearance in Australia. We look forward to providing initial data from the Heart-2 clinical trial in the first half of 2025. In addition, we are on track to initiate the Phase 1b clinical trial for our ANGPTL3 product candidate, VERVE-201, in the second half of this year, and we continue to advance our early-stage programs, including one targeting the LPA gene.”